BNP Paribas EasyStoxx Europe 600 UCITS ETF (C) (ETZ)

Now I know why it has been 18 years in conservatorship - we have a silent media and honest thoughts are suppressed under the guise of political. WE ARE IN GOVERNMENT CONSERVATORSHIP! NOW FLAG ME!

Sleeping Giant about to wake-up!!💯🚀

Sterling - please comment on todays news. tia

I think things are better now, do you agree?

On paper Morocco better team but in terms spirits Canada very high now! Canada can beat Morocco big upset of the week! We will see Saturday

AMFN has never even reached the starting line... They have yet to ever even come close to fusing anything. It's nothing but a scam to sell worthless stock.

.


.

Watch your wallet


Buyer Beware
Social Media Prom

How many shares does he have?..
When can he sell them?..

So what your thoughts on $TWOH now that Emil has dumped the CSE? We spent all this time screwing around with them only to get rid of it, when he should have focused on the US listing first, shareholders have been screwed over from multiple months due to this. Hoping somehow this POS goes on a wild r

The daily BTC nonsense will continue until BTC breaks out or goes to zero. I'm banking on a break out. The funny thing is all the ones saying it's going to zero own no crypto, never have and never had a central exchange account. My money and worth the risk. Too much happening around the world wi

Hard to speak on this with any confidence since there is so much we don’t know, but if the inspection has already been scheduled why did UNCY say in their pr that they will have to resubmit another SNA application?

As this isn't germane to BIEI, I'm done replying.

ASA Robotics
HK Tech 300 Profile: https://www.cityu.edu.hk/hktech300/start-ups/angel-fund-start-ups/asa-robotics-limited

Leidenford Limited
HK Tech 300 Profile: https://www.cityu.edu.hk/hktech300/start-ups/angel-fund-start-ups/leidenford-limited
New AWG launchin

Now knock down the subscription price to the $1.99 range.   Getting people familiar with the company is the top priority right now.....or should be 

It’s true. I do find this board entertaining. As for Anavex, I continue to believe nothing matters except a large, well designed and executed phase 3 trial in AD. Assuming Anavex is still around, which seems unlikely, and does the trial, which also seems unlikely, we may have an answer in the early

I missed that.   Let's see if they put out something a little more concrete.    

My take on 1st CRL vs this one -

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177749371

$UNCY - did some looking back - After the first CRL, the stock dropped from $6.80 to $4.77. After this second CRL, the drop was even steeper - from $7.70 to $4.70.

I believe this larger selloff happened because the press release vaguely stated the FDA didn't visit the site. When manag

I thought this was interesting considering everything unfolding with Kraig Labs these days…passing this along…after digging into some of the “what ifs” actually become reality..I asked Grok the following question..I will add that “if” this product is One of One..that’s monopoly? that’s moat? that’s

ModuLink's strategy is taking these tech innovations developed in CityU's engineering labs (like Leidenford's air water generator and ASA Robotics’ AI and robotics) and commercializing them.

City University of Hong Kong (CityU) is a major global force in deep-tech and applied research

Post of the Day — thank you, Srin!
Eyes on $BIEL!
Exceptionally well said. Post of the day. Thank you, srin!



BUY $BIEL$

Post of the day. Thank you, srin!
Eyes on. BIEL.
Splendidly stated!

BUY $BIEL$

U will see the power of upset team in soccer! Wait till end of the day!

$AEFI Overview here: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177724487

No change - no dilution since May 1, 2026 - 8 weekly updates!

Not sure where this info comes from but saw it in a story on Yahoo:
“ H.C. Wainwright, meanwhile, lowered its price target to $15 from $22 while keeping a 'Buy' rating. The firm sees potential launch delays of 5-12 months, but also emphasized that the FDA raised no new concerns on clinical ef